Home page > Anti-bribery Policy, Code of Ethics and Conduct and (Transparency Disclosures)

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data

Anti-bribery Policy, Code of Ethics and Conduct and (Transparency Disclosures)

The Code of Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature

The application of the following principles is guaranteed by the existence of procedures within the Group aimed at ensuring that its employees, internal bodies and third parties acting on its behalf, operate effectively in accordance with ethical principles.

This version of the Code has been approved by the Board of Directors of Chiesi Farmaceutici S.p.A., in 2021. This constitutes an official Group document and as such is binding upon all the bodies, employees, consultants, collaborators, agents and, at a more general level all third parties acting on behalf of the Group.

In order to uphold the high legal and moral standards of the Group, Chiesi also adopted an Anti-Bribery Policy in 2015. The purpose of this policy is to provide anyone acting on behalf of or in the interests of Chiesi with a series of general principles on how to recognise and deal with situations involving corruption and how to comply with related regulations.

 

Code of Conduct
Anti Bribery

 

EFPIA

As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) we are fostering the transparency on the interaction between the pharmaceutical industry and health care professionals & organisations according EFPIA, as well as all national legal regulations, as we are convinced to be independent partners with the same goal: cooperation and exchange of knowledge, as well as research and development without tortious interference or influence.

 

Disclosure DATA for the period since 1st of Januray 2020 to 31st December 2020

Disclosure DATA for the period since 1st of January 2019 to 31st December 2019

Disclosure DATA for the period since 1st of January 2018 to 31st December 2018

Disclosure DATA for the period since 1st of January 2017 to 31st December 2017

Disclosure DATA for the period since 1st of January 2016 to 31st December 2016

Disclosure DATA for the period since 2015.

 

INDIVIDUAL DISCLOSURE:

  • Donations and grants to HCO, HCP’s organisations and associations, organisations providing healthcare;
  • Costs related to Events: registration fees, sponsorship agreements, travel and accommodation;
  • Fees for Service and Consultancy to HCPs and HCOs: fees and related expenses must be disclosed separately. This is only applicable, when the HCPs or HCOs have provided their consent on the individual disclosure, otherwise the data needs to be published in the aggregated disclosure data.


AGGREGATE DISCLOSURE:

  • R&D costs: including costs for related events (investigators’ meetings, etc);
  • Transfers of value which cannot be disclosed on an individual basis for legal reasons.

For more questions on the EFPIA transparency codes or concerning a disclaimer or revocation of your consent to the individual disclosure, do not hesitate to contact us directly.